Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving Bisphosphonates for bone metastases

Journal of Oral and Maxillofacial Surgery

Volumn 70, Issue 12, 2012, Pages 2768-2775

  Morris, Patrick G ^a   Fazio, Maurizio ^b   Farooki, Azeez ^a   Estilo, Cherry ^a   Mallam, Divya ^a   Conlin, Alison ^a   Patil, Sujata ^a   Fleisher, Martin ^a   Cremers, Serge ^c   Huryn, Joseph ^a   Hudis, Clifford A ^a   Fornier, Monica N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BODY MASS; BONE METASTASIS; BREAST CANCER; DENTAL PROCEDURE; DENTURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; NEOPLASM; ORAL SURGERY; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84868709095     PISSN: 02782391     EISSN: 15315053     Source Type: Journal    
DOI: 10.1016/j.joms.2011.12.028     Document Type: Article

References (36)

1. T. Hamaoka, J.E. Madewell, D.A. Podoloff Bone imaging in metastatic breast cancer J Clin Oncol 22 2004 2942
2. P.G. Morris, H.L. McArthur, C.A. Hudis Therapeutic options for metastatic breast cancer Expert Opin Pharmacother 10 2009 967
3. M. Aapro, P.A. Abrahamsson, J.J. Body Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel Ann Oncol 19 2008 420
4. J.J. Body Effectiveness and cost of bisphosphonate therapy in tumor bone disease Cancer 97 2003 859
5. B.E. Hillner, J.N. Ingle, R.T. Chlebowski American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 2003 4042
6. G.N. Hortobagyi, R.L. Theriault, L. Porter et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases Protocol 19 Aredia Breast Cancer Study Group N Engl J Med 335 1996 1785
7. N. Kohno, K. Aogi, H. Minami Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial J Clin Oncol 23 2005 3314
8. L.S. Rosen, D. Gordon, M. Kaminski Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial Cancer 98 2003 1735
9. R.L. Theriault, A. Lipton, G.N. Hortobagyi et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial Protocol 18 Aredia Breast Cancer Study Group J Clin Oncol 17 1999 846
10. A.T. Stopeck, A. Lipton, J.J. Body Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study J Clin Oncol 28 2010 5132
11. S. Khosla, D. Burr, J. Cauley Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 2007 1479
12. A. Lipton, S. Siena, M. Rader Comparison of denosumab versus zoledronic acid (ZA) for treatment of bone metastases in advanced cancer patients: An integrated analysis of 3 pivotal trials Presented at the European Society of Medical Oncology 35th Annual Meeting Milan, Italy October, 2010 8 12 Abstract 3826
13. S.B. Woo, J.W. Hellstein, J.R. Kalmar Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws Ann Intern Med 144 2006 753
14. C.L. Estilo, C.H. Van Poznak, T. Wiliams Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy Oncologist 13 2008 911
15. K. Vahtsevanos, A. Kyrgidis, E. Verrou Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw J Clin Oncol 27 2009 5356
16. A. Lipton, L. Costa, S.M. Ali Bone markers in the management of metastatic bone disease Cancer Treat Rev 27 2001 181
17. L.M. Demers, L. Costa, V.M. Chinchilli Biochemical markers of bone turnover in patients with metastatic bone disease Clin Chem 41 1995 1489
18. L. Costa, L.M. Demers, A. Gouveia-Oliveira Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status J Clin Oncol 20 2002 850
19. C.L. Estilo, M. Fornier, A. Farooki Osteonecrosis of the jaw related to bevacizumab J Clin Oncol 26 2008 4037
20. S.L. Bonnick, L. Shulman Monitoring osteoporosis therapy: Bone mineral density, bone turnover markers, or both? Am J Med 119 2006 S25
21. J.E. Brown, R.J. Cook, P. Major Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors J Natl Cancer Inst 97 2005 59
22. R.J. Cook, R. Coleman, J. Brown Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer Clin Cancer Res 12 2006 3361
23. A. Lipton, R. Cook, F. Saad Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid Cancer 113 2008 193
24. R. Eastell, C. Christiansen, A. Grauer Effects of denosumab on bone turnover markers in postmenopausal osteoporosis J Bone Miner Res 26 2011 530
25. C.H. Van Poznak, S. Temin, G.C. Yee American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer J Clin Oncol 29 2011 1221
26. S. Baim, P.D. Miller Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw J Bone Miner Res 24 2009 561
27. S. Cremers, A. Farooki Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone Ann N Y Acad Sci 1218 2011 80
28. N.H. Bjarnason, E.E. Henriksen, P. Alexandersen Mechanism of circadian variation in bone resorption Bone 30 2002 307
29. D. Generali, A. Dovio, M. Tampellini Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases Br J Cancer 98 2008 1753
30. R.E. Marx, J.E. Cillo Jr, J.J. Ulloa Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment J Oral Maxillofac Surg 65 2007 2397
31. J.T. Grbic, D.M. Black, K.W. Lyles The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: Data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program J Am Dent Assoc 141 2010 1365
32. T.S. Lazarovici, S. Mesilaty-Gross, I. Vered Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates J Oral Maxillofac Surg 68 2010 2241
33. C.Y. Lee, J.B. Suzuki CTX biochemical marker of bone metabolism Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: A prospective clinical study Implant Dent 19 2010 29
34. J.V. Bagan, Y. Jiménez, D. Gómez Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates Oral Oncol 44 2008 1088
35. M.J. Seibel Clinical use of markers of bone turnover in metastatic bone disease Nat Clin Pract Oncol 2 2005 504
36. S. Khosla, D. Burr, J. Cauley Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment J Oral Maxillofac Surg 66 2008 1320